MIXED OUTCOME: Amgen Inc.'s fourth-quarter sales just topped Wall Street's expectations, rising 3 percent to $3.97 billion, but its adjusted income of $1.21 per share fell short by a penny. Its net
Stock Quote Search
Press ENTER To Search
Latest News
- Obama administration seeks online privacy rules
- Fuller Brush files for bankruptcy protection
- Hewlett-Packard Profit Forecast Falls Short of Analyst Estimates - San Francisco Chronicle
- AT&T CEO's 2011 Compensation Hurt By Failed T-Mobile Deal - NASDAQ
- Action Line: The Internal Revenue Service issues annual 'Dirty Dozen' ranking ... - San Jose Mercury News
- Housing takes another step out of the cellar - MarketWatch
- Historic door-to-door retailer Fuller Brush files for bankruptcy protection - Washington Post
- Yen edges up but stuck near 7-month low vs dollar - Reuters
- Calif. pledges better mobile privacy disclosures
- Ford to add $3.8B to pension plans this year
Site Search
Summary Box: Q4 costs rise, profit falls at Amgen
Created on Thursday, 26 January 2012 17:08Category: US Markets
income fell 9 percent to $934 million.
SALES TRENDS: Revenue rose from infection fighters Neulasta and Neupogen and five other drugs, but it fell or didn't change for three of Amgen's top four sellers.
2012 FORECAST: The Thousand Oaks, Calif., company, which is changing some top executives this year, expects to earn $5.90 to $6.15 per share, excluding one-time items, on revenue of about $16.3 billion.
Courtesy Yahoo Financial News